by Anthony S. Lubiniecki, ScD
Volume 2, Issue 2 (March/April 2003)
Over 25 years have elapsed since Kohler and Milstein electrified the immunology community with their article describing the reliable preparation of monoclonal antibodies (MAbs) by fusing immune splencytes with immortalized myeloma cells. This discovery not only garnered the pair of scientists a Nobel Prize, but also led to the development of a technology which has yielded a number of important therapeutic, prophylactic, and diagnostic products for in vivo human use, and hundreds of in vitro diagnostic products. Some of these products proved to be significant in meeting previously unmet medical needs, and a few have been commercial successes. But the path, from Kohler and Milstein’s discovery to commercial products, was discontinuous and a bit bumpy, and the technology continues to evolve…
Citation:
Lubiniecki AS. Monoclonal Antibody Products: Achievement and Prospects. BioProcess J, 2003; 2(2): 21-25. https://doi.org/10.12665/J22.Lubiniecki.